ARCHIVES

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

Core Grants Limit Formula Must Wait On Profiles

January 27, 1978

City of Hope CEO Michael Friedman: Cancer Centers Must Adapt; “Not Losing Sleep” Over Sequestration

April 5, 2013

NCI To Stop All Support For WHT After March 31

February 5, 1988

DCT Board Approves Phase 2/3 Studies Of LAK-IL-2

February 14, 1986

Obey Says NCI “Must Do Better,” Response Dispute GAO Conclusion

August 8, 1980

Neutron Therapy “Treatment Of Choice” In Salivary Gland Tumors – 100 Percent Complete Reponses

June 13, 1986